Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 3/20 | 0.47 |
| ▸ | TLR2 | O60603 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796689 | 1.00 | TLR4 (0.47) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL6797897 | 0.89 | MAPT (0.51) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL6797900 | 0.89 | MAPT (0.51) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL7365969 | 0.88 | TLR4 (0.47) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL7365963 | 0.88 | TLR4 (0.47) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL7365973 | 0.88 | TLR4 (0.47) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL6794718 | 0.88 | TLR4 (0.57) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL6794714 | 0.88 | TLR4 (0.57) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL7362736 | 0.88 | TLR4 (0.47) | TLR4TLR2MAPTMEN1KMT2A | |
| SCHEMBL7362733 | 0.88 | TLR4 (0.47) | TLR4TLR2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | TLR4 4105/4885TLR2 2204/4885MAPT 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.